Uterine Cancer Drugs Market
According to Intent Market Research, the Uterine Cancer Drugs Market is expected to grow from USD 19.8 billion in 2024-e at a CAGR of 4.3% to touch USD 26.6 billion by 2030. The Uterine Cancer Drugs Market is dominated by key players such as Pfizer Inc., Roche Holding AG, Merck & Co., Inc. and Bristol-Myers Squibb.